Katherine T. Landschulz, PhD

As therapeutic area lead for the Labcorp Biomarker Solution Center, Dr. Katherine Landschulz has overarching responsibility for the delivery of biomarker strategies for sponsor programs in cardiovascular, metabolic and renal diseases, nonalcoholic fatty liver diseases including NASH, as well as Alzheimer’s, Parkinson’s and other neurodegenerative disease indications. Kathy serves as a consultant to sponsors and teams, advising on biomarker selection and strategy development, laboratory placement of testing, feasibility designs, and overall guidance around translational and exploratory biomarker data in drug development. Additionally, she serves as a liaison, directing questions and connecting sponsors and Labcorp biomarker scientists. Finally, Kathy participates in enterprise-wide assessments, licensing and implementation of new laboratory biomarkers and tests transitioning from clinical trial to clinical care utilization. 

Kathy received her doctorate in human genetics/biology from Johns Hopkins University and School of Medicine, where she specialized in erythropoietin receptors on erythroid progenitor cells. Her postdoctoral areas of focus were molecular biology/lipogenesis at Johns Hopkins University School of Medicine and molecular biology/lipoproteins (HDL, VLDL) at The University of Texas Southwestern Medical Center.